R.Drake

9/2019-Ongoing: Principal Investigator

**TAURX THERAPEUTICS LTD. TRX-237-039**

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, 9-MONTH, BRAIN IMAGING AND SAFETY AND EFFICACY STUDY OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) (LMTM) IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE.

5/2019-Ongoing: Sub Investigator

**UCB BIOPHARMA SPRL EP0092**

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECIACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY

3/2019-Ongoing: Principal Investigator

**OTSUKA PHARMACEUTICAL 405-201-00015**

AN OPEN LABEL,52 WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WIT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER.

8/2017-2/2018: Principal Investigator

**F. HOFFMANN-LA ROCHE LTD BN29553**

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH

PRODROMAL TO MILD ALZHEIMER’S DISEASE

5/2017-8/2019: Principal Investigator

**ALKERMES ALK8700-A302**

A PHASE 3 STUDY IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TO EVALUATE THE TOLERABILITY OF ALKS 8700 AND DIMETHYL FUMARATE

2/2017-Ongoing: Principal Investigator

**EISAI E2609-G000-301**

A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE

2/2017-4/2017: Principal Investigator

**VTV THERAPEUTICS LLC TTP488-301**

RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTIN

11/2016-2017: Principal Investigator

**NOVARTIS COMB157G2301**

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

11/2016-3/2017: Sub Investigator

**ALLERGAN CGP-MD-01**

PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION

2/2016-7/2019: Principal Investigator

**SUVEN LIFE SCIENCES LTD**

A PHASE 2A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 26-WEEK, PLACEBO-CONTROLLED STUDY OF 50 MG AND 100 MG OF SUVN-502 IN SUBJECTS WITH MODERATE ALZHEIMER’S DISEASE CURRENTLY TREATED WITH DONEPEZIL HYDROCHLORIDE AND MEMANTINE HYDROCHLORIDE

1/2016-Ongoing: Principal Investigator

**EISAI E2609-G000-202**

A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED, PROOF-OF-CONCEPT, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF E2609 IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL ALZHEIMER’S DISEASE) AND MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE (REVISED PER AMENDMENT 01)

5/2016-Ongoing: Principal Investigator

**ALKERMES ALK8700-A301**

A PHASE 3 OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ALKS 8700 IN ADULTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

2/2015-6/2017: Sub Investigator

**MERCK 8931-017**

A RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND EFFICACY AND SAFETY TRIAL OF MK-8931 IN SUBJECTS MILD TO MODERATE ALZHEIMER’S DISEASE

11/2015- 6/2016: Sub Investigator

**MARINUS**

PROTOCOL 1042-0604 A FOLLOW-ON, TWO-YEAR OPEN-LABEL EXTENSION STUDY OF GANAXOLONE AS ADD-ON THERAPY IN ADULT PATIENTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES

11/2014: Principal Investigator

**ACORDA (DALF-PS-1016)**

A DOUBLE BLIND, PLACEBO CONTROLLED, PARALEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGHTS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POST-ISCHEMIC STROKE (MILESTONE)

12/2014: Principal Investigator

**BIOGEN 105MS401 (POP)**

PLEGRIDY (PEGINTERFERON β-1A) REAL WORLD EFFECTIVENESS AND SAFETY OBSERVATIONAL PROGRAM

3/2014-1/2015: Principal Investigator

**BIOGEN 109MS404 (RESPOND)**

A MULTI-CENTER, OPEN-LABEL, 12 MONTH ONSERVATIONAL STUDY EVALUATING THE CLINICAL EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES OF ORAL TECFIDERA (DIMETHYL FUMARATE) DELAYED-RELEASE CAPSULES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS AFTER SUBOPTIMAL RESPONSE TO GLATIRAMER ACETATE

4/2014-8/2017: Principal Investigator

**BIOGEN 109MS401 (ESTEEM)**

A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION OF TECFIDERA (DIMETHYL FUMARATE) WHEN USED IN A ROUTINE MEDICAL PRACTICE IN THE TREATMENT OF MULTIPLE SCLEROSIS (ESTEEM)

4/2014-5/2018: Principal Investigator

**MERCK 8931-019**

A PHASE II/III RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK 8931 IN SUBJECT WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL AD)

2/2014-6/2016: Sub Investigator

**MARINUS**

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF GANAXOLONE AS ADJUNCTIVE THERAPY FOR ADULTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT #1042-0603

2/2014-11/2014: Sub Investigator

**AVANIR PHARMACEUTICALS, INC**

A STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF NUEDEXTA (DEXTROMETHORPHAN 20MG/QUINIDINE 10MG) IN THE TREATMENT OF PSEUDOBULBAR AFFECT(PBA)

3/2014-10/2014: Sub Investigator

**LABRYS BIOLOGICS**

A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL-GROUP, STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF HIGH FREQUENCY EPISODIC MIGRAINE

3/2014-10/2014: Sub Investigator

**LABRYS BIOLOGICS**

A MULTICENTER, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED PARALLEL-GROUP, MULTI-DOSE STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF CHRONIC MIGRAINE

8/2013-2/2014: Sub Investigator

**UCB N01358**

A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (> 16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES

8/2103-2/2014: Sub Investigator

**UCB N01379**

AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY

8/2013-1/2015: Sub Investigator

**PFIZER A0081105**

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC CLONIC SEIZURE

3/2013-6/2013: Sub Investigator

**ALLERGAN GMA-BTX-CM-10-001**

AN OPEN LABEL, MULTICENTER STUDY OF THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF BOTOX (ONABOTULINUMTOXINA) FOR THE PROPHYLAXIS OF HEADACHES IN ADULT PATIENTS WITH CHRONIC MIGRAINE (THE COMPEL STUDY)

6/2012-6/2015: Principal Investigator

**NOVARTIS CFTY720DUS09**

A 12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (PREFERMS)

5/2012-6/2013: Sub Investigator

**UCB SP0980 (VIMPAT)**

A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATORY STUDY TO EVALUATE THE TOLERABLITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES

11/2010-10/2011: Sub Investigator

**NOVARTIS CFTY720DUS01**

A 6 MONTH, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTI-CENTER, STUDY TO EVALUATE PATIENT OUTCOMES, SAFETY AND TOLERABILITY OF FINGOLIMOD/DAY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO ARE CANDIDATES FOR MS THERAPY CHANGE FROM PREVIOUS DISEASE MODIFYING THERAPY (EPOC)